タカハシ　カンジ   TAKAHASHI KANJI   髙橋　寛二    所属   関西医科大学  眼科学講座    職種   非常勤講師
言語種別	英語
発表タイトル	The efficacy of intravitreal injection of aflibercept compared with ranibizumab on treatment naïve age-related macular degeneration with classic choroidal neovascularization.
会議名	The 8th ARVRS Congress(第52回日本網膜硝子体学会総会)
学会区分	全国規模の学会
発表者・共同発表者	◎Otsuji T, Koike N, Nishimura T, Takahashi K
発表年月日	2012/12
開催地 （都市, 国名）	名古屋
概要	Purpose: The efficacy of intravitreal injection of aflibercept (IVA) in the treatment of age-related macular degeneration (AMD) with choroidal neovascularization (CNV) that do not respond to ranibizumab has been reported. In those reports, most of the patients had CNV under the retinal pigment epithelium (RPE). We investigate the effect of IVA on the treatment naïve AMD with CNV above the RPE and compared the effect with intravitreal injection of ranibizumab (IVR). Methods: We reviewed the records of 36 eyes of 34 patients who received IVR and 4 eyes of 4 patients who received IVA. All patients had purely classic CNV and received three IVR or IVA treatments for their initial treatment.We reviewed the best-corrected visual acuity (BCVA) and central retinal thickness (CRT) measured by optical coherence tomography before the treatment and 1 month after the induction phase. We evaluated the efficacy of IVR and IVA on purely classic CNV retrospectively. Results: Among the patients who received IVR, the BCVA before and after the treatment was 0.66 and 0.43 logMAR, and the CRT was reduced from 409.9µm to 250.1 µm. Among the patients who received IVA, the BCVA before and after the treatment was 0.76 and 0.68 logMAR, and the CRT was reduced from 412.7µm to 202.0 µm. There were no significant differences of the change in BCVA and CRT between IVR and IVA patients. Conclusion: It can be concluded that IVA therapy could be as beneficial as IVR for AMD patients with classic CNV. IVR may be effective enough to treat AMD patients with classic CNV because IVA has longer serum half-life than IVR.